

Boston Scientific

PROMUS™ Everolimus-Eluting Stent Added to Boston Scientific Coronary Stent Portfolio

PROMUS Stent joins market-leading TAXUS® Paclitaxel-Eluting Coronary Stent Systems

PRNewswire-FirstCall
NATICK, Mass.
(NYSE:BSX)

NATICK, Mass., Sept. 1 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced plans for the anticipated International launch of its PROMUS™ (1) Everolimus-Eluting Coronary Stent System. The addition of the PROMUS Stent will expand the Company's drug-eluting stent (DES) portfolio to include two distinct drug platforms. Results from the SPIRIT II trial that compare the performance of Abbott's XIENCE™ V Everolimus-Eluting Coronary Stent System (distributed by Boston Scientific as the PROMUS Stent) to the TAXUS® Stent are expected to be announced at the upcoming European Society of Cardiology/World Congress of Cardiology meeting in Barcelona, Spain. Pending U.S. Food and Drug Administration (FDA) approval, the PROMUS Stent is expected to become available in the United States in 2008.

"We are excited to increase the breadth of our drug-eluting stent portfolio to include the PROMUS Stent," said Paul LaViolette, Boston Scientific Chief Operating Officer. "From the exceptional deliverability and proven outcomes of our market-leading TAXUS Stent System to the promising performance of the PROMUS Stent System, Boston Scientific will offer customers the most complete DES portfolio with which to treat their patients."

The PROMUS Stent is the latest in a series of new coronary stent technologies from Boston Scientific, which has launched a new DES product roughly every 12 to 18 months for the past three years. The company will continue to base its DES program and future pipeline on the market-leading TAXUS Stent, first introduced into the European marketplace as the TAXUS Express Stent System in 2003. The second-generation TAXUS Liberte™ Stent was launched internationally in 2005 and is expected to launch in the U.S. upon FDA approval, estimated in early 2007. To date, three million TAXUS Stents have been implanted in patients worldwide and clinical follow-up has been reported on more than 4,000 patients out to four years through the extensive TAXUS clinical trial series.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: <http://www.bostonscientific.com/>.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

CONTACT: Milan Kofol
508-650-8569
Investor Relations
Boston Scientific Corporation

Paul Donovan
508-650-8541
Media Relations
Boston Scientific Corporation

(1) PROMUS™ Stent is pending CE-Mark. Not available for sale in the European economic area (EEA); E-Mark pending for PROMUS Stent.

SOURCE: Boston Scientific Corporation

CONTACT: investors, Milan Kofol, +1-508-650-8569, or media, Paul Donovan, +1-508-650-8541, both of Boston Scientific Corporation

Web site: <http://www.bostonscientific.com/>

<https://news.bostonscientific.com/news-releases?item=58880>

